MODIFICATION OF FEEDING BEHAVIOUR

• US 20110021420A1
• Filed: 09/03/2010
• Published: 01/27/2011
• Est. Priority Date: 01/10/2003
• Status: Abandoned Application

• Current Assignee: Imperial Innovations Limited (Imperial College London)
• Original Assignee: Imperial Innovations Limited (Imperial College London)
• Inventors: Small, Caroline Jane, Ghatei, Mohammad Ali, Bloom, Stephen Robert, Dakin, Catherine Louise
• Application Number:
  US12/875,636
• Publication Number:
  US 20110021420A1
• Time in Patent Office: Days
• US Class Current: 514/4.9
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/2271 Neuropeptide Y
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.

Claims

1-37. -37. (canceled)

38. A method for weight control or treatment, in a subject, comprising administering an effective amount of an oxyntomodulin and one or more additional agents chosen from a Glucagon-like peptide-1 (GLP-1), a GLP-1 agonist, an amylin, a leptin, or an exendin-4.

39. The method of claim 38, wherein the oxyntomodulin and the one or more additional agents has one or more of the following effects:

decreases calorie intake or food intake;

prevents or reduces weight;

induces weight loss;

controls appetite, satiety or hunger, reduces weight;

reduces or prevents obesity;

or increases energy expenditure.

40. The method of claim 38, wherein the oxyntomodulin is a human oxyntomodulin.

41. The method of claim 38, wherein the oxyntomodulin comprises the sequence of SEQ ID NO:

9.

42. The method of claim 38, wherein the weight control or treatment t is achieved by reducing levels of circulating ghrelin.

43. The method of claim 38, wherein the oxyntomodulin is administered via a route peripheral to the brain.

44. The method of claim 43, wherein the oxyntomodulin is administered by oral, rectal, intravenous, intramuscular, intraperitoneal, buccal, sublingual, nasal, subcutaneous, or transdermal administration, or by inhalation.

45. The method of claim 38, wherein the one or more additional agents is administered via a route peripheral to the brain.

46. The method of claim 38, wherein the one or more additional agents is administered by oral, rectal, intravenous, intramuscular, intraperitoneal, buccal, sublingual, nasal, subcutaneous, or transdermal administration, or by inhalation.

47. The method of claim 38, wherein the one or more additional agents is administered at a dose of 0.1 nmoles or more per kg body weight of the subject.

48. The method of claim 38, wherein the one or more additional agents is administered at a dose of up to 3.2 nmoles per kg body weight of the subject.

49. The method of claim 38, wherein the oxyntomodulin is administered at a dose of 0.1 nmoles or more per kg body weight of the subject.

50. The method of claim 38, wherein the oxyntomodulin is administered at a dose of up to 12 nmoles per kg body weight of the subject.

51. The method of claim 38, wherein the oxyntomodulin is administered before a meal.

52. The method of claim 38, wherein the oxyntomodulin is administered at a dose of 0.5 mg to 2 mg before a meal.

53. The method of claim 38, wherein the oxyntomodulin and the one or more additional agents is administered simultaneously.

54. The method of claim 38, wherein the oxyntomodulin and the one or more additional agents is administered sequentially in any order.

55. The method of claim 38, which comprises administering GLP-1, or an agonist thereof.

56. The method of claim 38, which comprises administering amylin.

57. The method of claim 38, which comprises administering leptin.

58. The method of claim 38, which comprises administering exendin-4.

59. The method of claim 38, which further comprises administering PYY or an agonist thereof.

60. The method of claim 38, wherein the subject is a human.

61. The method of claim 60, wherein the subject is a overweight, obese or a diabetic.